Mutation in Plasmodium falciparum BTB/POZ domain of K13 protein confers artemisinin resistance,Antimicrobial Agents and Chemotherapy

当前位置： X-MOL 学术 › Antimicrob. Agents Chemother. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Mutation in Plasmodium falciparum BTB/POZ domain of K13 protein confers artemisinin resistance
Antimicrobial Agents and Chemotherapy ( IF 4.1 ) Pub Date : 2021-10-04 , DOI: 10.1128/aac.01320-21
Lucie Paloque _{1,

2,

3} , Romain Coppée ₄ , Barbara H Stokes ₅ , Nina F Gnädig ₅ , Karamoko Niaré ₆ , Jean-Michel Augereau _{1,

2,

3} , David A Fidock _{5,

7} , Jérôme Clain _{4,

8} , Françoise Benoit-Vical _{1,

2,

3}

Affiliation

Partial artemisinin resistance, defined in patients as a delayed parasite clearance following artemisinin-based treatment, is conferred by non-synonymous mutations in the Kelch beta-propeller domain of the Plasmodium falciparum k13 (pfk13) gene. Here, we ...

中文翻译：